How We Fund ALS Research
Make a Difference
PLEASE NOTE:
As of November 23, 2009, ALS Canada has a new address and phone number:
3000 Steeles Avenue East, Suite 200
Markham, Ontario L3R 4T9
Phone: 905-248-2052   Fax: 905-248-2019

How We Fund ALS Research

The ALS Society of Canada is committed to investing our research funds where they will have the most impact.

The ALS Society of Canada funds excellent and relevant peer-reviewed research.

The ALS Society of Canada funds research that is evaluated at a high level using international evaluation methods adopted by the CIHR.

Relevant Information

Within the Neuromuscular Research Partnership the ALS Society of Canada along with Muscular Dystrophy Canada fund only research relevant to neuromuscular disease.

Again evaluation methods are used to rank proposals on their relevance to understanding, treatment and cure for neuromuscular diseases, particularly ALS.

All research funded by the ALS Society of Canada is peer-reviewed (as stated in the policies of the organization), meaning that a panel of qualified individuals review all research proposals using appropriate criteria to determine excellence and relevance and rank them accordingly.

These are all safe-guards designed to insure that donor funds directed to research will advance our understanding and get us closer to treatments or a cure for ALS.

Another way we increase the impact of our donors’ gifts is to partner with others or to find matching dollars.
 

THE NORTHERN NEURON - ALS RESEARCH IN CANADA

ALS Research News - The latest ALS als research articles.
1.  Study Links Neurodegeneration in Head Trauma and ALS

Nearly four years since researchers identified the mystery component of toxic protein aggregates in ALS and frontotemporal lobar degeneration (FTLD)-affected motor neurons as TAR DNA-binding protein ( ◊

"Study Links Neurodegeneration in Head Trauma and ALS"
2.  New Genes, Proteins and Biomarkers

Buried deep within thick skulls and boney spines, the neurons of the central nervous system are, perhaps, the most protected cells of the body. This is good news for healthy neurons, but bad news for ◊

"New Genes, Proteins and Biomarkers"
3.  A clinical study of Ceftriaxone in ALS

A clinical study of Ceftriaxone in ALS. ◊

"A clinical study of Ceftriaxone in ALS"
4.  ALS Vaccine To Target Misfolded SOD1

Mutations in the gene encoding superoxide dismutase cause approximately 20 per cent of familial ALS cases, according to a paper recently published in Human Molecular Genetics. ◊

"ALS Vaccine To Target Misfolded SOD1"
5.  Is BMAA a neurotoxin relevant to ALS?

Cyanobacteria, also known as the blue-green algae that smother ponds, lakes and seas around the world, produce several toxins. Among them is beta-methylamino-L-alanine (BMAA), an amino acid that some ◊

"Is BMAA a neurotoxin relevant to ALS?"
6.  Neurodegenerative Disease Research Accelerates

While scientists worldwide strive to understand neurodegeneration and find ways to slow or stop it, variations in how they perform experiments and interpret their findings can slow the global effort t ◊

"Neurodegenerative Disease Research Accelerates"
7.  ALSUntangled investigates stem cell transplants in Mexico and Germany

Although stem cell transplants might eventually represent an effective treatment for ALS, many challenges need to be overcome, such as how to deliver the cells into motor areas throughout the nervous ◊

"ALSUntangled investigates stem cell transplants in Mexico and Germany"
8.  Guidelines for preclinical animal research

We know more about the biology underlying ALS than ever before, but little of this knowledge has been translated into effective treatments for patients. ◊

"Guidelines for preclinical animal research"